Outsourcing Pharma
Fueled by increasing investments from biotech, Charles River expects to double the size of its business over the next five years – organically and through M&A – to become a ‘more responsive partner,’ says CEO.
Charles River eyes global M&A opportunities, expects to double size in 5 years
Media Coverage
